Cargando…
The RareCyte® platform for next‐generation analysis of circulating tumor cells
Circulating tumor cells (CTCs) can reliably be identified in cancer patients and are associated with clinical outcome. Next‐generation “liquid biopsy” technologies will expand CTC diagnostic investigation to include phenotypic characterization and single‐cell molecular analysis. We describe here a r...
Autores principales: | Kaldjian, Eric P., Ramirez, Arturo B., Sun, Yao, Campton, Daniel E., Werbin, Jeffrey L., Varshavskaya, Paulina, Quarre, Steven, George, Tad, Madan, Anup, Blau, C. Anthony, Seubert, Ronald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586054/ https://www.ncbi.nlm.nih.gov/pubmed/30277660 http://dx.doi.org/10.1002/cyto.a.23619 |
Ejemplares similares
-
The Parsortix™ Cell Separation System—A versatile liquid biopsy platform
por: Miller, M. Craig, et al.
Publicado: (2018) -
Blood‐based biopsies—clinical utility beyond circulating tumor cells
por: Tang, Cha‐Mei, et al.
Publicado: (2018) -
How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
por: Zeune, Leonie L., et al.
Publicado: (2018) -
Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte(®) Platform
por: Kaldjian, Eric P., et al.
Publicado: (2022) -
Centrifugation affects the purity of liquid biopsy‐based tumor biomarkers
por: Rikkert, Linda G., et al.
Publicado: (2018)